An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Summary

An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine

Timeline

Start

2016-12

Primary completion

2018-04

Completion

2019-03

Publications

• Starling AJ, Kudrow D, Kapur N, Awad SF, Grossman SW, Patel F, Ailani J, Blumenfeld A, Lipton RB. Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial. Pain Ther. 2026 Jun;15(3):785-801. doi: 10.1007/s40122-026-00831-0. Epub 2026 Apr 17.
• Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol. 2022 Jul 8;22(1):251. doi: 10.1186/s12883-022-02774-3.
• Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5.
• Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021 Mar 19;21(1):126. doi: 10.1186/s12883-021-02123-w.

Drugs

Indications